High dose radioimmunotherapy in relapsed B-cell lymphoma with I-131 Rituximab

被引：0
|
作者：
W. Becker
Th. Behr
机构：
[1] Department of Nuclear Medicine,
[2] University of Göttingen,undefined
[3] Germany,undefined
[4] e-mail: wbecker@med-uni-goettingen.de,undefined
[5] Phone: +49/551/39-8510,undefined
[6] Fax: +49/51/39-8526,undefined
来源：
Annals of Hematology | 2001年 / 80卷 / Suppl 3期
关键词：
Lymphoma; High Dose Radioimmunotherapy;
D O I：
10.1007/PL00022777
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：B130 / B131
相关论文
共 50 条
  • [21] Monte Carlo single-cell dosimetry of I-131, I-125 and I-123 for targeted radioimmunotherapy of B-cell lymphoma
    Bousis, Christos
    Emfietzoglou, Dimitris
    Nikjoo, Hooshang
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2012, 88 (12) : 908 - 915
  • [22] Tandem myeloablative 131I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients
    Deshayes, Emmanuel
    Kraeber-Bodere, Francoise
    Vuillez, Jean-Philippe
    Bardies, Manuel
    Teulon, Isabelle
    Pouget, Jean-Pierre
    IMMUNOTHERAPY, 2013, 5 (12) : 1283 - 1286
  • [23] Tandem high dose chemotherapy and myeloablative radioimmunotherapy with 131-I-anti-CD20 rituximab in relapsed and refractory B-cell lymphoma:: Interim results of a phase II study of the German RIT study group
    Hohloch, K
    Wulf, G
    Glass, B
    Jung, W
    Stitz, E
    Meller, J
    Sahlmann, C
    Trümper, L
    Griesinger, F
    ANNALS OF ONCOLOGY, 2005, 16 : 135 - 135
  • [24] Repeated radioimmunotherapy (RIT) with 131I-rituximab for patients with low grade and aggressive relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL)
    Kang, Hye Jin
    Lee, Seung-Sook
    Kim, Kyeong Min
    Lim, Sang Moo
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [25] RADIOIMMUNOTHERAPY DOSE ESTIMATION IN PATIENTS WITH B-CELL LYMPHOMA
    SIEGEL, JA
    GOLDENBERG, DM
    BADGER, CC
    MEDICAL PHYSICS, 1993, 20 (02) : 579 - 582
  • [26] POST THERAPY IMAGING IN HIGH-DOSE I-131 RADIOIMMUNOTHERAPY PATIENTS
    EARY, JF
    POLLARD, KR
    DURACK, LD
    BICE, AN
    LEWELLEN, TK
    MATTHEWS, D
    PRESS, OW
    NELP, WB
    APPELBAUM, FR
    BERNSTEIN, I
    MEDICAL PHYSICS, 1994, 21 (07) : 1157 - 1162
  • [27] Radioimmunotherapy with 131I-anti-CD20 rituximab in B-cell lymphoma: Results of the goettingen RAIT study group.
    Griesinger, F
    Behr, T
    Jung, W
    Glass, B
    Truemper, LH
    Meller, J
    Woermann, B
    Kaufmann, CC
    Binder, C
    Brittinger, G
    Becker, W
    BLOOD, 2002, 100 (11) : 313B - 313B
  • [28] Personalized dosimetry of 131I-rituximab radioimmunotherapy of lymphoma
    Boucek, J. A.
    Turner, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S261 - S262
  • [29] Guideline for radioimmunotherapy of rituximab relapsed or refractory CD20+ follicular B-cell nonHodgkin's lymphoma
    Fischer, M
    Behr, I
    Grünwald, F
    Knapp, WH
    Trümper, L
    von Schilling, C
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2004, 43 (05): : 171 - 176
  • [30] Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab
    Quackenbush, Robert C.
    Horner, Thierry J.
    Williams, Vanessa C.
    Giampietro, Patricia
    Lin, Thomas S.
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 779 - 781
12345